Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 26;13:933648. doi: 10.3389/fphar.2022.933648

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Ji, Liang, Lv, Ding, Lai, Li, Zeng, Lv and Sheng.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Network meta-analysis of a comparison of different treatments on PFS, OS, DCR, and ⩾3 AEs in patients with radioiodine-refractory differentiated thyroid cancer. (A) Pooled estimates of the network meta-analysis of progression-free survival (PFS) and overall survival (OS). Data on each cell is a hazard ratio (HR) (95% CrIs) for the comparison of row-defining treatment versus column-defining treatment. The HR less than 1 favors upper-row treatment. Significant results are highlighted in bold. (B) Reconstruction of the Kaplan–Meier curve of PFS for each treatment with median PFS. (C) Reconstruction of the Kaplan–Meier curve of OS for each treatment. (D) Pooled estimates of the network meta-analysis of the disease control rate (DCR) and grade 3 or higher adverse events (⩾3 AEs). Data on each cell is an odds ratio (OR) (95% CrIs) for the comparison of row-defining treatment versus column-defining treatment. The OR greater than 1 favors upper-row treatment. Significant results are highlighted in bold.